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Eliminating hepatitis B virus as a global health threat
In The Lancet Infectious Diseases, Shevanthi Nayagam 
and colleagues1 report a modelling study on the 
eﬀ ectiveness of diﬀ erent interventions on the incidence 
and mortality rate of chronic hepatitis B virus (HBV) 
infec tion. To appreciate the implications of this 
report, we need to understand the context. Chronic 
viral hepatitis is the seventh leading cause of death 
worldwide.2 Chronic HBV infection alone aﬀ ects over 
240 million people worldwide and is one of the most 
common causes of cirrhosis and liver cancer.3 In May, 
2014, the World Health Assembly requested WHO 
to provide the necessary technical support to enable 
member states to develop robust national viral hepatitis 
prevention, diagnosis, and treatment strategies. In 
response, WHO set ambitious goals of reducing new 
cases of chronic viral hepatitis by 90%, and reducing 
mortality rates from these infections by 65% between 
2015 and 2030.4 Achievement of these goals might at 
least eliminate chronic viral hepatitis as a major global 
health threat. What can we do to make this happen?
Nayagam and colleagues1 ﬁ rst assessed the situation 
at present and compared it with a hypothetical situation 
where no intervention had previously been used to 
combat HBV.1 It is gratifying to note that current 
interventions have already had a huge impact: averting 
210 million new chronic HBV infections by 2015 and 
1·1 million deaths between 2015 and 2030. Nonetheless, 
63 million new cases and 17 million HBV-related deaths 
will still occur between 2015 and 2030. The authors then 
evaluated ﬁ ve strategies, including scaling-up infant 
vaccination coverage to 90%, birth-dose vaccination 
coverage to 80%, peripartum antivirals coverage for 
mothers with positive hepatitis B e antigen to 80%, 
increasing access to antivirals to 80%, and developing 
a cure for HBV infection. The ﬁ rst three interventions 
target new infections, whereas HBV treatments prevent 
disease progression, cirrhotic complications, and liver 
cancer.
Compared with the present state, scaling-up infant 
vaccination can prevent 4·3 million new infections 
from 2015 to 2030, but the real impact comes from 
birth-dose vaccination, which prevented 18·7 million 
new cases of HBV infection. The smaller eﬀ ect of infant 
vaccination compared with birth-dose vaccination 
is because infant vaccination is ineﬀ ective against 
mother-to-child transmission, which is the primary 
route of transmission in endemic areas. Even with 
vaccination or hepatitis B immunoglobulin at birth, 
women with very high viral loads might still transmit 
HBV to their children,5 and the use of antivirals during 
late pregnancy has been shown to almost eliminate 
mother-to-child transmission in this situation.6,7 In 
Nayagam and colleagues’ model,1 peripartum antivirals 
can further prevent 0·6 million new cases. Further 
studies are needed to deﬁ ne the long-term safety of 
peripartum antivirals in mothers and children. Based 
on these data, low-income countries should prioritise 
birth-dose vaccination over peripartum antivirals if they 
do not have the resources to implement both strategies 
at the same time because the birth-dose vaccination will 
have a bigger impact than peripartum antivirals.
Because most cases of cirrhosis and liver cancer 
occur during or after middle age, prevention of new 
infections will not have a major eﬀ ect on HBV-related 
mortality rates until decades later. Management of 
patients who have already been infected is, therefore, 
important. Although only one placebo-controlled trial 
has used clinical outcomes as the primary endpoint,8 
several observational studies suggest that antivirals 
can reduce the risk of liver cancer and mortality.9 The 
main drawback of antiviral therapy is that long-term 
treatment is often needed, but drug resistance and 
side eﬀ ects are rare with entecavir or tenofovir, which 
makes long-term treatment acceptable.10 Based on 
the estimations in Nayagam and colleagues’ study, 
providing antivirals to 80% of patients with treatment 
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indications can meet the goal of reducing HBV-
related mortality rate by 65% by 2030. Conversely, 
development of a cure for chronic hepatitis B would not 
have an additional eﬀ ect on mortality rate. This is hardly 
surprising because the authors assume that adequate 
HBV suppression by available antivirals is as eﬀ ective 
as curing HBV. However, antivirals reduce, but do not 
eliminate, the risk of liver cancer,11 so the eﬀ ect of curing 
HBV should be revisited when such a drug becomes 
available.
We commend the authors for extensively reviewing 
data from diﬀ erent regions and providing information 
that is urgently needed.1 But knowing the eﬀ ectiveness 
of the strategies is only the ﬁ rst step. The beneﬁ ts 
will not materialise if the interventions are not 
implemented. Some policies that sound straightforward 
in the developed world can face major hurdles in low-
income and middle-income countries. For example, 
the transportation of vaccines to remote areas and 
temperature control can already be a challenge, not 
to mention the need to train health-care providers 
and educate the public. Patient management would 
not be possible without access to diagnostic tests 
and monitoring instruments. Safe needles and blood 
products should be available to all countries. Finally, these 
programmes cannot be sustained without adequate 
funding. According to Nayagam and col leagues’ forecast, 
the annual expenditure between 2015 and 2030 needed 
to achieve the goals will be US$5·5 billion. Although this 
will be a good investment because cirrhosis and liver 
cancer could be avoided, governments still need to ﬁ nd 
ways to ﬁ nance these programmes.
With determination, the WHO 2030 goals for 
chronic viral hepatitis can be and should be achieved. 
Achievement of this goal calls for concerted eﬀ ort from 
policy makers, clinicians, and societies. The tools to 
combat HBV are already at hand, and now is the time for 
action.
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The rigorous analysis of evidence by Kali Zhou and col-
leagues1 is a benchmark endeavour that reveals both the 
evidence-based interventions that improve hepatitis 
B virus (HBV) and hepatitis C virus (HCV) testing and 
linkage to care and treatment (ie, the care cascade), and 
the major remaining gaps in this knowledge base. This 
analysis arrives at a crucial time for public health. The 
global burden of viral hepatitis is huge. Over 400 million 
people have HBV or HCV infection.2 In 2013, about 
1·4 million people died of HBV-related or HCV-related 
liver cancer and other diseases, surpassing deaths from 
HIV, tuberculosis, and even road injuries.2,3 Testing 
